Drug
Sirexatamab clinical trials
Also written DKN-01 and LY2812176.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Leap Therapeutics, Inc. (7) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Johannes Gutenberg University Mainz (1)
Often tested with
Tested in the same studies.
Pembrolizumab (2) · Paclitaxel (2) · Gemcitabine (1) · Cisplatin (1) · Tislelizumab (1) · Nivolumab (1)
Studies
Open first, then newest update. How each study uses sirexatamab is read from its arms, and is right about nine times in ten.
Testing it · 10
- Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05761951Written as DKN-01
- A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal CancerTerminatedPhase 2Leap Therapeutics, Inc.NCT04363801Written as DKN-01 300mg
- Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)TerminatedPhase 2Massachusetts General HospitalNCT04057365Written as DKN-01
- Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or GallbladderCompletedPhase 1Leap Therapeutics, Inc.NCT02375880Written as DKN-01
- Phase 2 Study of DKN-01 in Colorectal CancerCompletedPhase 2Leap Therapeutics, Inc.NCT05480306Written as DKN-01
- A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 1Leap Therapeutics, Inc.NCT01711671Written as DKN-01 300 mg
- A Study of DKN-01 in Combination With Paclitaxel or PembrolizumabCompletedPhase 1Leap Therapeutics, Inc.NCT02013154Written as DKN-01 150 mg
- A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or CarcinosarcomaCompletedPhase 2Leap Therapeutics, Inc.NCT03395080Written as 300mg DKN-01
- DKN-01 Inhibition in Advanced Liver CancerStatus unknownPhase 1/2Johannes Gutenberg University MainzNCT03645980Written as DKN-01 300 mg
- A Study of DKN-01 in Multiple Myeloma or Advanced Solid TumorsCompletedPhase 1Leap Therapeutics, Inc.NCT01457417Written as DKN-01
Given in every arm · 2 — sirexatamab is usual care beside what is tested
- A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1TerminatedPhase 1/2NYU Langone HealthNCT03837353Written as DKN-01
- Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric CancerWithdrawnPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT03818997Written as DKN-01
Codes
What other systems call sirexatamab · ClinicalTrials.gg INT017809
- UNII (FDA) RM898LZ4SISIREXATAMABOne source FDA
- NCI Thesaurus C99123SirexatamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RM898LZ4SI | SIREXATAMAB | One source FDA |
| NCI Thesaurus | C99123 | Sirexatamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.